This white paper positions Malaysia as an emerging hub for early-phase clinical research. It outlines the country’s regulatory environment, streamlined approval timelines, and growing network of trial-ready sites. The paper highlights Malaysia’s diverse patient population, high-quality investigators, and competitive operating costs as key differentiators. It also reviews infrastructure investments, government incentives, and alignment with international GCP standards. The analysis concludes that Malaysia offers a compelling alternative for sponsors seeking speed, quality, and regional access for Phase I and early Phase II studies.

Join for free to read